Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: IPSEN
Woman and Man Max 99 years
IPSEN PHARMA SAS
Update Il y a 4 ans
A phase III, multicentre, prospective, double blind, randomised, placebo controlled study, assessing the efficacy and safety of Dysport intramuscular injections used for the treatment of lower limb spasticity in adult subjects with spastic hemiparesis due to stroke or traumatic brain injury
The primary study objective is to assess the efficacy of Dysport compared to placebo at Week 4 on the change from baseline in the gastrocnemius-soleus complex (GSC) muscle tone (knee extended) in hemi...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
IPSEN PHARMA S.A.S
Update Il y a 4 ans
Study to evaluate the efficay, safety and local tolerability of triptorelin pamoate (11,25mg) injected sub cuteanously in patients with (locally advanced or metastatic) prostate cancer
To confirm the efficacy of triptorelin pamoate (11.25 mg)prolonged release (PR) formulation by inducing castration (defined as serum testosterone level of <50 ng/dL or <1.735 nmol/L) at Day 29 and mai...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
IPSEN PHARMA SAS
Update Il y a 4 ans
An interventional non-therapeutic study to assess ex vivo basophil activation in response to various preparations of taspoglutide Uno studio interventistico non terapeutico destinato a valutare l’attivazione ex vivo dei basofili in risposta alle preparazioni di taspoglutide
To assess the occurrence of positive reaction (basophil activation signal) to various taspoglutide formulations (including taspoglutide used in Phase III clinical trials, extra-pure (EP) taspoglutid...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
IPSEN PHARMA S.A.S
Update Il y a 4 ans
An international multi-center, open-label study to evaluate safety, tolerability, biodistribution (distribution in the body), dosimetry (to calculate the radiation exposure of patients) and preliminary efficacy of 177Lu-OPS201 for the therapy of somatostatin receptor-positive neuroendocrine tumors (NETs). Eine internationale multizentrische, offene Studie zur Bewertung der Sicherheit, Verträglichkeit, Biodistribution (Verteilung im Körper), Dosimetrie (zur Berechnung der Strahlenbelastung der Patienten) und der vorläufigen Wirksamkeit von 177Lu-OPS201 für die Therapie Somatostatin-Rezeptor-positiver neuroendokriner Tumore (NETs)
To assess the safety and tolerability of peptide receptor radionuclide therapy (PRRT) with 177Lu-OPS201 administered in three cycles in patients with somatostatin receptor positive NETs (including pha...
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
IPSEN PHARMA SAS
Update Il y a 4 ans
PROSTATE CANCER ANTIGEN-3 (PCA-3) AND TMPRSS2-ERG (T2-ERG) SCORE CHANGES DURING INITIATION OF ANDROGEN DEPRIVATION THERAPY (ADT) WITH TRIPTORELIN 22.5MG IN PATIENTS WITH ADVANCED PROSTATE CANCER (PCA): A PHASE III, SINGLE ARM MULTICENTRE STUDY
To model the PCA3 score change at 6 months post-treatment using a multivariate linear model and the following variables outcomes at baseline: age, Prostate Specific Antigen (PSA), clinical stage (TNM)...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
IPSEN PHARMA SAS
Update Il y a 4 ans
A study to assess efficacy of diosmectite (Smecta®) in the symptomatic treatment of acute diarrhoear in adults
The primary objective of the study is to demonstrate that diosmectite efficacy is superior to placebo regarding the time to recovery of an acute diarrhoea episode presumed of infectious origin in adul...
Country
None
organs
None
Specialty
None
unknown
More information
Man
Between 18 years
and 99 years
IPSEN
Update Il y a 4 ans
IPSEN Triptocare : Essai de phase 3 évaluant l’efficacité d’un traitement hormonal par de la triptoréline, chez des patients ayant un cancer de la prostate avancé. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Prostate cancer antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) score changes during initiation of androgen deprivation therapy (ADT) with triptorelin 22.5mg in patients with advanced prostate cancer (PCA)...
Country
France
organs
Prostate
Specialty
Hormonothérapie
Essai clos aux inclusions
More information
Woman
Between 18 years
and 99 years
IPSEN
Update Il y a 4 ans
IPSEN X-55-58064-00 : Essai de phase 2 randomisé comparant l’efficacité et la tolérance d’un traitement par un inhibiteur de la sulfatase à de l’acétate de mégestrol, chez des patientes ayant un cancer de l’endomètre avancé ou en rechute. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase II international multicentre randomised open label study of oral steroid sulphatase inhibitor BN83495 versus megestrol acetate (MA) in women with advanced or recurrent endometrial cancer.
Country
France
organs
Appareil génital féminin - autres
Specialty
Thérapies Ciblées
,
Hormonothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
IPSEN NV
Update Il y a 4 ans
AN INTERNATIONAL, MULTICENTRIC, PROSPECTIVE, OPEN LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 MG ASSOCIATED TO STANDARD OF CARE IN THE TREATMENT OF CLINICAL SYMPTOMS ASSOCIATED WITH INOPERABLE MALIGNANT INTESTINAL OBSTRUCTION
To assess the efficacy of lanreotide Autogel lanreotide Autogel 120 mg for the relief of vomiting due to inoperable malignant intestinal obstruction in patients without nasogastric tube AND to assess ...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3